- Home
- QUCY vs CNSP Comparison
QUCY vs CNSP Comparison
Compare QUCY & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QUCY | CNSP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Germany | United States |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.9M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | QUCY | CNSP |
|---|---|---|
| Price | $3.41 | $4.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 30.0M | 2.1M |
| Earning Date | 06-26-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.34 | N/A |
| Revenue Next Year | $171.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.73 |
| 52 Week High | $3.97 | $10.59 |
Technical Indicators
Market Signals| Indicator | QUCY | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 93.25 | 54.46 |
| Support Level | $0.39 | $2.01 |
| Resistance Level | N/A | $8.56 |
| Average True Range (ATR) | 0.46 | 0.97 |
| MACD | 0.30 | -0.00 |
| Stochastic Oscillator | 67.06 | 32.95 |
Price Performance
Historical ComparisonAbout QUCY Mainz Biomed N.V. Ordinary Shares
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.